Kymera Therapeutics, Inc. Common Stock

KYMRNASDAQ • USD
127.57 USD
↗ 0.40 (0.32%)AT CLOSE (03:59 PM EST)
127.61
↗ 0.04 (0.03%)
POST MARKET (AS OF 07:59 PM EST)
Post Market
AS OF 07:59 PM EST
127.61
↗ 0.04 (0.03%)
🔴Market: CLOSED

KYMR is currently priced at $127.63. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, KYMR is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 13, 2026.

Open?$126.93
High?$129.78
Low?$124.90
Prev. Close?$127.17
Volume?808.8K
Avg. Volume?956.5K
VWAP?$128.14
Rel. Volume?0.85x
Bid / Ask
Bid?$92.72 × 400
Ask?$127.57 × 900
Spread?$34.85
Midpoint?$110.15
Valuation & Ratios
Market Cap?10.9B
Shares Out?85.4M
Float?67.1M
Float %?80.7%
P/E Ratio?N/A
P/B Ratio?6.75
EPS?-$4.09
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Employees
285
Market Cap
10.9B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-08-21
Address
500 NORTH BEACON STREET, 4TH FLOOR
WATERTOWN, MA 02472
Phone: 857-285-5314
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
73
Short Sent.?
53
Piotroski F-Score?0/9Weak
Altman Z-Score?41.65Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?12.52%High
Short Interest?8.4M
Days to Cover?10.5
Free Float67.1M
Avg Daily Volume800.7K
Settlement Date2026-10-30
Financial Health
Current Ratio?11.13Strong
Quick Ratio?11.13Strong
Cash Ratio?4.16Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
28
6.75FAIR▾
P/S?
Peers
100
S&P
3
106.53HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-26.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
102.89HIGH▾
Returns & Efficiency
ROE?
S&P
7
-21.6%WEAK▾
ROA?
S&P
3
-19.8%WEAK▾
Cash Flow & Enterprise
FCF?$-288893000
Enterprise Value?$10.5B
Fundamentals ratios updated end of day